A boceprevir failure in a patient infected with HCV genotype 1g: Importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy

Valeria Cento, Simona Landonio, Francesca De Luca, Velia C. Di Maio, Valeria Micheli, Carmen Mirabelli, Fosca Niero, Carlo Magni, Giuliano Rizzardini, Carlo F. Perno, Francesca Ceccherini-Silberstein

Research output: Contribution to journalArticlepeer-review

Abstract

A patient classified as HCV-1a-positive by both LiPA Siemens 2.0 and Abbott RealTime HCV Genotype II was instead found to be infected with HCV-1g, as determined by phylogenetic analysis of NS3 sequences. HCV-1g NS3 sequences available to date naturally harbour the resistance substitution T54S, plus P131S and L135F changes, located in the highly conserved NS3 positions within the boceprevir-binding site, as determined by structural modelling. HCV-1g NS3 sequences show some similarities to HCV-4 and arepoorly responsive to interferon/ribavirin and to boceprevir/telaprevir; this patient was also a nullresponder to boceprevir treatment. Baseline genotypic resistance testing may provide crucialinformation for the management of first-generation protease-inhibitorbased regimens, including both HCV genotype/subtype and natural resistance.

Original languageEnglish
Pages (from-to)645-648
Number of pages4
JournalAntiviral Therapy
Volume18
Issue number4
DOIs
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'A boceprevir failure in a patient infected with HCV genotype 1g: Importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy'. Together they form a unique fingerprint.

Cite this